Huperzine A has been proven superior to drugs licensed for the treatment of Alzheimer’s, including the leading anticholine sterase drugs physostigmine and tacrine. Huperzine A improved learning and memory in mice better than tacrine. Unlike physostigmine and tacrine, Huperzine A acts specifically on AchE in the brain rather than AchE found elsewhere in the body i.e., far less is wasted on irrelevant effects. Unlike physostigmine and tacrine, Huperzine A does not appear to bind to receptors in the central nervous system, which can cause adverse side effects. Its effects last 10 to 12 times longer than physostigmine and tacrine (up to 8 hours).

[Main Function]

1)huperzine A can improve memory, thinking, and behavioral function in people with
   Alzheimer's disease, multi-infarct dementia, and senile dementia, and increase
   the level of the neurotransmitter acetylcholine by blocking its breakdown.

2) It may also protect neurons from cell death caused by toxic levels of glutamate
    and protect against some of the effects of chemical nerve agents used in warfare,
    such as soman.

3) It is also the treatment of AD in a randomized controlled trial of its effect
    on cognitive function.